Pneumology
Maria Molina Molina / Jordi Dorca Sargatal
PRINCIPAL INVESTIGATORS
- Ana Córdoba Izquierdo
- Noelia Cubero De Frutos
- Jordi Dorca Sargatal
- Eva Farrero Muñoz
- Rosa Mª López Lisbona
- Mariana Mercedes Muñoz Esquerre
- Jesús Ribas Solà
- Guillermo Suárez Cuartín
- Vanesa Vicens Zygmunt
CLINICAL RESEARCHERS
- Roger Llatjos Sanuy
- Joaquim Llauradó Ovejas
- Marta López Sánchez
- Carmen Monasterio Ponsa
- Susana Padrones Sánchez
- Rosa Planas Balague
- Enric Prats Soro
- Neus Salord Oleo
POSTDOCTORAL RESEARCHERS
- Ana Montes Worboys
PREDOCTORAL RESEARCHERS
- Samantha Aso González
- Esther Cuevas Sales
- Mercè Gasa Galmes
- Carlos Machahua Huamani
- Lourdes Planas Cerezales
- Yolanda Ruíz Albert
SCIENTIFIC SUPPORT
- Monsterrat Navarro Rodríguez
- Jesús Ríos Martín
- Maria Jose Rodriguez Lopez
MANAGEMENT SUPPORT
- Maria Del Mar Chicote Guerra
Translational Medicine
Cardiovascular, Respiratory and Systemic Diseases and cellular aging
Scientific production
43
PAPERS
Average IF: 8,232
15
LED PAPERS
Average IF: 4,710
4 PUBLICATIONS IN FIRST DECILE
17 PUBLICATIONS IN FIRST QUARTILE
30 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Senage,T;Paul,A;Le Tourneau,T;Fellah Hebia,I; Vadori,M; Bashir,S; Galinanes,M et al, The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration, Nat. Med., 2022;28(2):283-294, doi:10.1038/s41591-022-01682-w
- Cottin,V;Tomassetti,S;Valenzuela,C;Walsh,S;Antoniou,K;Bonella,F;Brown,KK et al, Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective., Am. J. Respir. Crit. Care Med., 2022;206(3):247-259, doi:10.1164/rccm.202111-2607PP
- Raghu,G;Remy Jardin,M; Richeldi,L; Thomson,CC; Inoue,Y; Johkoh,T; Kreuter,M et al, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am. J. Respir. Crit. Care Med., 2022;205(9):18-47, doi:10.1164/rccm.202202-0399ST
- Rüschoff,JH;Haberecker,M;Tsourti,Z;Nackaerts,K;de Perrot,M; Brcic,L; Nadal,E et al, Expression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project., Mod. Pathol., 2022;35(12):1888-1899, doi:10.1038/s41379-022-01145-0
- Khor,YH;Bissell,B;Ghazipura,M;Herman,D;Hon,SM;Hossain,T;Kheir,F et al, Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis., Ann Am Thorac Soc, 2022;19(5):833-844, doi:10.1513/AnnalsATS.202102-172OC
Research highlights
PROJECTS
1 Granted competitive projects
8 Ongoing competitive projects
9 Started clinical trials
27 Ongoing clinical trials
2 ongoing non competitive projects
PUBLISHED WORKS
3 Clinical Guidelines
INNOVATION
1 Patent
1 License
1 Spin-off
NETWORKS
CIBERER
Selected projects
- FIS22094. Integración de las características moleculares, genómicas, morfológicas, y ambientales para mejorar el diagnóstico y tratamiento de precisión en Enfermedades Pulmonares Intersticiales Difusas fibrosantes (Precision-EPID). Instituto de Salud Carlos III (ISCIII). Budget: 3049970. 2023-2025. PI: Molina Molina, Maria.
- 20FIS038. EFECTO DE LORATADINA EN LINFANGIOLEIOMIOMATOSIS. Instituto de Salud Carlos III (ISCIII). Budget: 263603,37. 2020-2023. PI: Molina Molina, Maria.
- 19FIS033. Caracterización de la fibrosis pulmonar telomérica y su regulación biológica. Instituto de Salud Carlos III (ISCIII). Budget: 177870. 2019-2022. PI: Molina Molina, Maria.
- FIS21100. LOOKING FOR PREDICTIVE FACTORS AND PREVENTIVE MEASURES OF POSTCOVID19 INTERSTITIAL LUNG SEQUELAE. (POST-COVIL). Instituto de Salud Carlos III (ISCIII). Budget: 151250. 2022-2024. PI: Molina Molina, Maria.
- 17ACL032. ESTUDIO OBSERVACIONAL EN VOLUNTARIOS SANOS Y PACIENTES CON EPOC PARA EVALUAR LA RELACIÓN ENTRE LAS MEDICIONES CLÍNICAS, RADIOLÓGICAS Y DE BIOMARCADORES Y LA PROGRESIÓN DEL ENFISEMA DURANTE UN PERIODO DE DOS AÑOS. Boehringer Ingelheim España, S.A. Budget: 118222,88. 2017-2022. PI: Santos Pérez, Salud.